It is made available under a CC-BY 4.0 International license .

1

2 Title: Projected Impact of Nonpharmacologic Management of Stage 1 Hypertension

Among Lower-Risk US Adults 3

Short Title: Nonpharmacologic Management of Hypertension 4

- Kendra D. Sims, PhD, MPH*^{1,2}; Pengxiao Carol Wei, MPH*¹; Joanne M. Penko, MS, MPH¹; 5
- Susan Hennessy, PhD¹; Pamela G. Coxson, PhD¹; Nita H. Mukand, PharmD, MBA, MPH¹; 6
- Brandon K. Bellows, PharmD, MS³; Dhruv S. Kazi, MD, MSc, MS⁴; Yiyi Zhang, PhD³; Ross 7
- Boylan, PhD¹; Andrew E. Moran, MD, MPH³; Kirsten Bibbins-Domingo, PhD, MD, 8 MAS 1,5,6,7
- 9
- 10
- *these authors contributed equally as first authors to this work 11
- 12

Affiliations: 13

- 14 1. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 15
- 2. Department of Epidemiology, Boston University School of Public Health, Boston, MA 16
- 3. Department of Medicine, Division of General Medicine, Columbia University Irving 17 Medical Center, New York, New York 18
- 4. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of 19 20 Cardiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 21
- 5. Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, San 22 Francisco, California 23
- 6. UCSF Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital, 24 25 San Francisco, California
- 7. Editorial Board, Journal of the American Medical Association, Chicago, Illinois 26
- 27
- Address for correspondence: 28
- 29 Kendra D. Sims, PhD
- 30 Boston University School of Public Health
- 31 715 Albany St. Boston, MA 02118
- 32 Phone: (617) 358-3301 | Email: ksims17@bu.edu
- 33

34 Word count: 2847

- 35
- 36
- 37
- 38

It is made available under a CC-BY 4.0 International license .

39 Abstract

- 40 **Background:** The 2017 American College of Cardiology (ACC)/American Heart Association
- 41 (AHA) guidelines newly classified 31 million US adults as having stage 1 hypertension. The
- 42 ACC/AHA guidelines recommend behavioral change without pharmacology for the low-risk
- 43 portion of this group. However, the nationwide reduction in cardiovascular disease (CVD) and
- 44 associated healthcare expenditures achievable by evidence-based dietary improvements,
- 45 sustained weight loss, adequate physical activity, and alcohol moderation remain unquantified.
- 46 We estimated the effect of systolic BP (SBP) control and behavioral changes on 10-year CVD
- 47 outcomes and costs.
- 48 **Methods:** We used the CVD Policy Model to simulate CVD events, mortality, and healthcare
- 49 costs among US adults aged 35-64. We simulated interventions on a target population, identified
- from the 2015-2018 National Health and Nutrition Examination Survey, with low-risk stage 1
- systolic hypertension: defined as untreated SBP 130-139 mmHg and diastolic BP <90 mmHg; no
- 52 history of CVD, diabetes, or chronic kidney disease; and low 10-year risk of CVD. We used
- 53 published meta-analyses and trials to estimate the effects of behavior modification on SBP. We
- assessed the extent to which intermittent healthcare utilization or partial uptake of
- nonpharmacologic therapy would decrease CVD events prevented.
- **Results:** Controlling SBP to <130 mmHg among the estimated 8.8 million U.S. adults (51%
- women) in the target population could prevent 26,100 CVD events, avoid 2,900 deaths, and save
- 58 \$1.6 billion in healthcare costs over 10 years. The Dietary Approaches to Stop Hypertension
- 59 (DASH) diet could prevent 16,000 CVD events among men and 12,000 among women over a
- 60 decade. Other nonpharmacologic interventions could avert between 3,700 and 19,500 CVD
- events. However, only 5.5 million (61%) of the target population regularly utilized healthcare
- 62 where recommended clinician counseling could occur.
- **63 Conclusions:** As only two-thirds of U.S. adults with Stage 1 hypertension regularly receive
- medical care, substantial benefits to cardiovascular health and associated costs may only stem
 from policies that promote widespread adoption and sustained adherence of nonpharmacologic
- 65 from policies that promote widespread adoption and sustained adherence of nonpharmacologic 66 therapy. Future work should quantify the population-level costs, benefits, and efficacy of
- 67 improving the food system and local infrastructure on health behavior change.
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75

It is made available under a CC-BY 4.0 International license .

76 Clinical Perspective:

77 What is new? (<100 words)

78 79 80 81 82 83 84 85 86	 Guidelines recommend modifying health behaviors to achieve blood pressure control in individuals with stage 1 hypertension, but the nationwide reduction in cardiovascular disease (CVD) and associated healthcare expenditures achieved remain unquantified. Using a public policy simulation model of CVD, we projected that controlling stage 1 systolic hypertension with nonpharmacologic therapy among an initially low-risk population of nearly 9 million young- and middle-aged adults would avert approximately 26,000 CVD events, 3000 deaths, and \$1.6 billion in healthcare costs over 10 years. The Dietary Approaches to Stop Hypertension (DASH) diet could provide the greatest population benefit.
87	
88	What are the clinical implications? (<100 words)
 89 90 91 92 93 94 95 96 97 98 99 	 Evidence-based health behaviors, such as adopting the unprocessed foods-centric Dietary Approaches to Stop Hypertension (DASH) diet, could provide long-term dividends to improved cardiovascular health. However, one-third of initially low-risk adults with stage 1 hypertension did not regularly use healthcare. There additionally are documented challenges to sustaining these lifestyle changes. Systemic deprivation of health-promoting resources in the social and built environment can pose insurmountable economic barriers for marginalized patients, perpetuating cardiovascular disparities. The recommended medical provider counseling on behavioral modification must be paired with community interventions, infrastructure improvements, and nutrition-promoting food system policies to promote adherence.
100	
101	
102	
103	
104	
105	
106 107	Keywords: cardiovascular disease, hypertension, clinical guidelines, public policy, behavioral intervention
108 109 110 111	Non-standard Abbreviations and Acronyms : ACC/AHA, American College of Cardiology and American Heart Association (ACC/AHA); SBP, systolic blood pressure; DBP, diastolic blood pressure; DASH, Dietary Approaches to Stop Hypertension; NHANES, National Health and Nutrition Examination Survey

It is made available under a CC-BY 4.0 International license .

112 Introduction

134

The 2017 American College of Cardiology and American Heart Association (ACC/AHA) 113 guidelines reinforced the importance of blood pressure (BP) control for disease prevention by 114 lowering the hypertensive threshold¹. Compared with the Seventh Report of the Joint National 115 Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) 116 BP classification, the ACC/AHA guidelines newly categorizes 31 million US adults as having 117 stage 1 hypertension (systolic BP [SBP]/diastolic BP [DBP] 130/80-139/89 mmHg)^{2,3}. 118 However, the guidelines recommend pharmacotherapy only for the small subset of this group 119 who are 65 years and older, have a history of cardiovascular disease (CVD), diabetes, chronic 120 kidney disease, or a 10-year risk of CVD of at least 10 percent. For the rest of this patient base, 121 clinicians are instead advised to provide counseling on lifestyle changes based on findings from 122 short-term behavioral intervention trials⁴. These nonpharmacologic therapies include the Dietary 123 Approaches to Stop Hypertension (DASH) diet⁵, sufficient physical activity⁶, balancing dietary 124 intake of potassium to sodium⁷, sustaining loss of excess body weight⁸, and ceasing excessive 125 alcohol consumption⁹. The potential long-term population health and economic benefits of 126 127 scaling up behavioral intervention trial findings for the population with stage 1 hypertension not recommended pharmacotherapy remain unquantified¹⁰. Additionally, the extent to which lack of 128 129 regular healthcare access might limit opportunities to identify stage 1 hypertension and counsel 130 nonpharmacologic therapies that prevent CVD has not been ascertained for this group. Using a public policy simulation model of CVD and data from the National Health and 131 Nutrition Examination Survey (NHANES), we first described the US adult population with stage 132 1 systolic hypertension (SBP 130-139 mmHg and DBP <90 mmHg) who would be 133

4

recommended only nonpharmacologic therapy by the 2017 ACC/AHA BP guideline. We then

It is made available under a CC-BY 4.0 International license .

projected the effect of SBP control via nonpharmacological therapy on CVD incidence, CVD
mortality, and healthcare costs over 10 years. We also assessed the attenuated impact of
recommended medical provider counseling on nonpharmacologic therapy in this population due
to lack of regular healthcare utilization.

139

140 Methods

141 Model overview

The CVD Policy Model is a state-transition computer simulation model of coronary heart 142 143 disease (CHD) and stroke incidence, recurrence, mortality, and direct healthcare costs in all US adults aged 35-94 years^{11–15}. Core model inputs are estimated from nationally representative 144 databases, longitudinal cohort studies, and natural history studies (Supplemental Table S2). For 145 146 the population without CVD, the model predicts the annual incidence of CHD, stroke, and non-CVD mortality via competing risk models. We base estimates on age, sex, and CVD risk factors, 147 using risk functions calculated from data pooled and harmonized from several National Heart, 148 Lung, and Blood Institute (NHLBI) observational cohorts^{16–20}. The population distribution of 149 CVD risk factors (i.e., SBP, DBP, self-reported use of antihypertensive medications, low- and 150 high-density lipoprotein cholesterol, exposure to tobacco smoke, and diabetes status) are derived 151 from the NHANES 2015-2016 and 2017-2018 cycles²¹. By incorporating expected population 152 growth as well as changes in risk factors and event rate, the model projects subsequent CVD 153 154 events, coronary revascularization procedures, and mortality from CVD and non-CVD causes in annual cycles (Supplemental Figure S1). Direct healthcare costs associated with acute CVD 155 events are derived from the National Inpatient Sample (NIS) and costs associated with chronic 156 CVD and background (non-CVD) healthcare are derived from the Medical Expenditure Panel 157

It is made available under a CC-BY 4.0 International license .

158	Survey (MEPS) ^{22,23} . The model was calibrated to reproduce annual CVD event rates within 1%
159	of observed hospital discharges in NIS (2012-2016) and deaths observed in US National Vital
160	Statistics System (2018) ^{22,24,25} . The study was considered exempt by the Institutional Review
161	Board at the University of California, San Francisco. We followed the Consolidated Health
162	Economic Evaluation Reporting Standards (CHEERS) reporting guideline for health economic
163	evaluations ²⁶ .

164

165 Model inputs and target population

Key model inputs are described in Supplemental Table S2. The target population is US 166 167 adults aged 35-64 years with untreated stage 1 systolic hypertension (SBP 130-139 mmHg and 168 DBP <90 mmHg) for whom only nonpharmacological therapy (e.g., dietary changes, increasing physical activity, weight loss) is recommended by the 2017 ACC/AHA BP guideline¹. We 169 limited our study to stage 1 systolic hypertension due to insufficient evidence for 170 nonpharmacologic therapy on DBP on CVD outcomes or long-term CVD outcomes associated 171 with stage 1 isolated diastolic hypertension (SBP <130 mmHg and DBP 80-89 mmHg)²⁷. The 172 mean of all available measures for each NHANES participant was used for BP. Operationally, 173 we used the subsample of NHANES of appropriate age and blood pressure ranges; no reported 174 current medications to treat high BP; no history of CVD, diabetes, or chronic kidney disease; and 175 the contemporaneous criteria for <10% predicted risk of a CVD event in 10 years²⁸ 176 (Supplemental Table S3). 177 Based on current US guidelines for physical activity²⁹ and diet³⁰, we estimated the 178

- proportion of men and women in the target population who are insufficiently active (<600
- 180 metabolic equivalent minutes of task [METS] per week), overweight or obese (body mass index

It is made available under a CC-BY 4.0 International license .

181	[BMI] \geq 25 kg/m ²), and who consume excessive sodium (\geq 2300 mg/day), inadequate potassium
182	(<3400 mg/day for men; <2600 mg/day for women), lower than recommended amounts of fruits
183	and vegetables (<2 cups of fruit and/or <2.5 cups of vegetables per day), and excessive alcohol
184	(>2 drinks/day for men; >1 drink/day for women; 14 grams of alcohol = 1 drink). We assumed
185	that no one in the target population adhered to the DASH diet based on low reported intake of
186	fruits and vegetables and excessive sodium in NHANES. We implemented a classification of
187	regular access to healthcare previously used in NHANES ³¹ , based on participants confirming
188	having some form of health insurance, at least one routine place they receive healthcare, and at
189	least one visit to a healthcare professional in a non-emergency room context in the past year.

190

191 Simulated comparators

We simulated a baseline "status quo" scenario that incorporated SBP changes expected 192 with demographic shifts as the target population ages. We compared the status quo with the 193 194 mean SBP reduction from trial and meta-analysis data of nonpharmacological management among individuals in the target population not meeting recommended thresholds for specific 195 health behaviors (Supplemental Table S1). Adopting the DASH dietary pattern reduced SBP by 196 5.5 mmHg ³². Sustained weight loss among adults with a BMI \geq 25 kg/m² reduced SBP by 4.8 197 mmHg³³. Reduced dietary sodium among adults with excessive intake reduced SBP by 4.2 198 mmHg³⁴. Increased fruit and vegetable consumption among adults with insufficient dietary 199 potassium reduced SBP by 2.8 mmHg³². Adequate physical activity among adults who do not 200 engage in sufficient weekly METS reduced SBP by 3.8 mmHg³⁵. Reduced alcohol consumption 201 among adults consuming more than recommended drinks weekly reduced SBP by 3.1 mmHg³⁶. 202 203 The total population effect of an intervention was therefore dependent both on the size of the

It is made available under a CC-BY 4.0 International license .

SBP reduction and number of individuals exhibiting the modifiable risk. Since the mean SBP in the target population overall is less than 4 mmHg above 130 for both men and women, some of these effect sizes reduced blood pressure below the 129 SBP target assumed in the initial analysis. As trial and meta-analysis data of nonpharmacological management did not quantify either selection into their studies or long-term adherence, we simulated in sensitivity analyses control to 129 SBP assuming 50% of the intervenable target population adhered to each intervention over 10 years.

We also compared the "status quo" scenario with a scenario controlling SBP to <130 211 212 mmHg (i.e., max SBP set to 129 mmHg) each year for all individuals in the target population. We conservatively assumed that those whose risk factor profile changed so that they would be 213 eligible for pharmacological intervention according to the 2017 ACC/AHA BP guideline (e.g., 214 developed diabetes) would initiate medications, resulting in an SBP <130 mmHg with no change 215 216 to their other risk factors. We also simulated controlled SBP <130 mmHg only among those with 217 regular access to healthcare. This set of analyses assessed the full benefit of the entire target population achieving the goals outlined by the 2017 ACC/AHA guidelines, as well as how 218 focusing on counseling in the healthcare setting would attenuate the extent of CVD events 219 220 prevented and healthcare costs saved.

221

222 Statistical analyses

We simulated a nationally representative dynamic cohort of US adults over 10 years, starting in 2018 and running through 2027. For each intervention, we calculated the difference in (1) incident and total CVD events, (2) CVD mortality, and (3) associated direct healthcare costs

It is made available under a CC-BY 4.0 International license .

226 relative to the status quo. Using Monte Carlo methods, we repeated the analyses 1000 times, randomly selecting model input parameters with replacement from pre-specified distributions 227 scaled to the mean and confidence interval (Supplemental Table S3) and generated 95% 228 229 uncertainty intervals around model estimates. We used normal distributions for baseline SBP and mean SBP changes expected for nonpharmacologic therapy 21,32-36; lognormal distributions for 230 the relative risks of CHD, ischemic stroke, and hemorrhagic stroke associated with SBP changes 231 37 ; and lognormal distributions for healthcare utilization costs 22,23 . 232 233 The CVD Policy Model is programmed using the Intel Fortran Compiler Classic 2021.5 234 and Monte Carlo simulations are run using Python version 3.10. We estimated model inputs

using Stata 17 and SAS version 9.4 and analyzed outcomes using Microsoft Excel version 2108.

237 **Results**

The simulated target population represents an estimated 4.2 million men and 4.6 million 238 women aged 35-64 years. Table 1 presents the gender-stratified clinical and behavioral 239 characteristics. Only 40% reported adequate intake of fruits and vegetables. Four-fifths had a 240 BMI classified as either overweight or obese. Men were more likely than women to consume 241 excess sodium (92% versus 71%) and alcohol (28% versus 17%). Insufficient physical activity 242 was more prevalent among women than men (45% versus 30%). Only 51% of men and 73% of 243 244 women in the target population were both insured and had visited their routine, non-emergency healthcare provider within the past year. 245

By focusing on stage 1 systolic hypertension, we target approximately half of the total population for whom the ACC/AHA 2017 guidelines recommend behavioral change. These

It is made available under a CC-BY 4.0 International license .

248	guidelines would classify an additional 3.9 million men and 3.2 million women at low-CVD risk
249	as having stage 1 isolated diastolic hypertension (Supplemental Table S4).

- 250 Compared with the status quo among US adults with stage 1 hypertension recommended
- nonpharmacologic therapy, controlling SBP to 129 mmHg is projected to prevent 26,100 (95%

252 CI: 22,600 – 30,700) incident CVD events and 2,900 (95% CI: 2,400 – 3,300) CVD deaths over

10 years (Table 2). Averting these CVD events and mortality would save an estimated \$1.6 (95%)

254 CI: \$1.4 – \$1.9) billion in hospitalizations, procedures, outpatient care, and background

healthcare costs. Figure 1 displays how not intervening among men and women who did not

regularly utilize healthcare would reduce incident CVD events prevented by each evidence-based

intervention by 39%. By intervening only via provider counseling, the projected number of CVD

events and CVD deaths prevented by controlling SBP to <130 mmHg was reduced, respectively,

259 to 15,800 (95% CI: 13,800 – 18,600) and 1,800 (95% CI: 1,600 – 2,000).

Full adoption of the DASH diet is the nonpharmacologic therapy that would translate to 260 the greatest mean SBP reduction, preventing a projected 28,000 (95% CI: 18,100 - 38,400) CVD 261 events and saving 1.8 (95% CI: 1.2 - 2.4) billion in healthcare costs (Table 3, Figure 1). 262 Implementing an intervention that sustained weight loss would prevent 19,500 (95% CI: 15,200 263 -24,200) CVD events over 10 years. The other nonpharmacologic therapies are projected 264 prevent thousands of CVD events and mortality, with hundreds of millions of dollars in 265 266 healthcare savings. We quantified in Supplemental Figure S2 the magnitude to which health and economic benefit would be drastically attenuated by only achieving 50% adherence of each 267 268 intervention.

269

It is made available under a CC-BY 4.0 International license .

270

271 Discussion

272 Nearly 9 million US adults aged 35-64 years with stage 1 systolic hypertension would be recommended nonpharmacological therapy by the 2017 ACC/AHA BP guideline because of 273 younger age and lower CVD risk. We projected that controlling SBP to <130 mmHg could 274 prevent over 26,000 CVD events compared with the status quo. Universal adoption of the DASH 275 diet was projected to prevent 28,000 CVD events over 10 years. Sustained weight loss, sodium 276 reduction, and increased fruit and vegetable intake could also offer significant population 277 benefits. Finally, relying solely on behavioral counseling at healthcare encounters might fail to 278 reach the half of men and one-quarter of women with stage 1 systolic hypertension at low CVD 279 280 risk who do not regularly engage with the healthcare system.

As the JNC7 BP guideline explicitly stated prehypertension was not a disease category¹, 281 the lower BP threshold to define hypertension in the 2017 ACC/AHA BP guideline is an 282 example of medicalization that effectively created a new medical diagnosis for those previously 283 considered disease-free ³⁸. A new diagnosis of hypertension may change incentives in physician-284 patient interactions. However, many providers have limited training in in effective health 285 counseling, let alone in tailoring recommendations for diverse patient populations³⁹. A common 286 critique of medicalization is that racial and ethnic minorities and people of lower socioeconomic 287 288 status (SES) face more barriers that prevent them from fulfilling these 'prescribed' health 289 behavior changes. Furthermore, the population most in need of nonpharmacological BP control is often uninsured, and does not regularly access healthcare for counseling opportunities to 290 $occur^{40}$. 291

It is made available under a CC-BY 4.0 International license .

292 Policies that improve the food system and neighborhood conditions may facilitate recommended behavior changes irrespective of whether a person regularly interacts with a 293 healthcare provider. Though salt alternatives can provide a more favorable ratio of dietary 294 potassium to sodium among those who cook at home⁴¹ population benefits may be minimal 295 among groups reliant on processed foods without commitment from stakeholders in restaurant 296 and food manufacturing industries⁴². The US Food and Drug Administration has recently 297 announced voluntary sodium reduction guidelines for commercially produced and packaged 298 299 foods, involving gradually reducing maximum sodium content to allow consumer tastes to adapt and focusing on per-package versus per-serving sodium content⁴³. Similar industry-oriented 300 policies in the United Kingdom were associated with modest annual reductions in sodium levels 301 detected in population-representative urine samples between 2003 and 2007⁴⁴. 302

Community members are more likely to be more physically active if they reside in 303 economically invested areas that are well-connected by sidewalks, with adequate street lighting 304 and lower levels of crime^{45,46}. Amenities within walking distance that have been associated with 305 lower prevalence of physical inactivity and obesity include destinations for errands, green spaces 306 such as parks, outdoor features such as beaches and trails, and a public transit system that is 307 proximate to employment^{47,48}. Racial and ethnic minorities as well as low socioeconomic status 308 people are concentrated in areas with more barriers to walking, fewer free physical activity 309 facilities, and limited available healthy food choices^{46,49}. Marginalized people also often report 310 having less time and resources to engage in recommended health behaviors⁵⁰. Multilevel public 311 health strategies that restructure the disadvantaged environmental context for vulnerable groups 312 are vital to redress CVD disparities. These public health approaches can synergistically achieve a 313 broader population reach than the individual behavior change interventions that provided inputs 314

It is made available under a CC-BY 4.0 International license .

for our analysis. Quantifying the cost of such population-level interventions would enableestimation of cost-effectiveness.

317

318 Limitations

319 Our study integrated several nationally representative data sources into a platform that 320 simulated the future impact of potential population-level interventions on blood pressure control. 321 However, NHANES only provides participant self-report of health behaviors such as diet and 322 physical activity, which may be subject to reporting bias. We modeled 50% and 100% uptake of each nonpharmacological intervention and assumed sustained SBP reduction over 10 years, 323 which may be difficult to achieve in practice. Our results may therefore represent projections of 324 325 the upper limit of population benefits with independent interventions. We used meta-analysis and trial results to simulate SBP reductions with nonpharmacologic therapy, where information on 326 long-term adherence was unavailable. Though our methods could only simulate the independent 327 328 impact of each intervention, nonpharmacological SBP management realistically necessitates a combination of health behaviors: e.g., weight reduction via sufficient exercise in conjunction 329 with dietary modification. Our analysis only included individuals with stage 1 hypertension 330 according to the 2017 ACC/AHA BP guideline; however, if implemented population-wide, 331 nonpharmacological therapy could have even greater benefit by preventing CVD events among 332 333 individuals with normal and elevated BP as well as patients already on antihypertensive therapy.

334

335 Conclusions

It is made available under a CC-BY 4.0 International license .

336	We used a computer simulation model to project the potential health and economic
337	benefits of implementing evidence-based nonpharmacological therapy among nearly 9 million
338	US adults with stage 1 systolic hypertension. Each intervention has the potential to prevent
339	between 3,700 and 28,000 CVD events. Full adherence of the DASH diet could save up to 3,100
340	lives and advert upwards of \$1.7 billion in healthcare costs over 10 years. However, as only two-
341	thirds of these individuals regularly interact with the healthcare system, achieving the full benefit
342	via recommended provider counseling may remain elusive. Even among those in care,
343	marginalized people systematically lack the individual- or community-level resources needed to
344	modify their health behavior. For maximal population benefit, food system policies that improve
345	accessibility to nutrient-rich food as well as lower sodium choices will facilitate large-scale
346	adoption. Policymakers, industry stakeholders, and medical professionals need to collaborate on
347	strategies to manage blood pressure among this large group of adults vulnerable to long-term
348	CVD risk. Broad public health interventions on the local and federal infrastructure would likely
349	result in substantial benefits not only for adults with Stage 1 hypertension, but for the U.S.
350	population at large.
351	
352	
353	
354	
355	
356	

It is made available under a CC-BY 4.0 International license .

357	Disclosures: None
358	Funding statement: This work was funded by National Institutes of Health grant
359	K99AG083121 (PI: Sims)
360	
361	
362	
363	
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	
375	
376	

It is made available under a CC-BY 4.0 International license .

377 **References**

378 1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 379 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 380 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of 381 382 the American College of Cardiology/American Heart Association Task Force on Clinical Practice 383 Guidelines. Journal of the American College of Cardiology. 2018;71:e127–e248. 384 2. Ritchey MD, Gillespie C, Wozniak G, Shay CM, Thompson-Paul AM, Loustalot F, Hong Y. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 385 386 2017 ACC/AHA Hypertension Guideline. J Clin Hypertens (Greenwich). 2018;20:1377–1391. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, Whelton PK. Potential U.S. 387 3. 388 Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Journal of the American 389 *College of Cardiology*. 2018;71:109–118. 390 4. Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Behavioral Counseling to Promote a 391 Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Systematic Review for the U.S. Preventive 392 393 Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 394 2017 [cited 2021 Dec 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK476368/ 395 5. Schwingshackl L, Chaimani A, Schwedhelm C, Toledo E, Pünsch M, Hoffmann G, Boeing H. 396 Comparative effects of different dietary approaches on blood pressure in hypertensive and pre-397 hypertensive patients: A systematic review and network meta-analysis. Crit Rev Food Sci Nutr. 2019;59:2674-2687. 398 399 Barone Gibbs B, Hivert M-F, Jerome GJ, Kraus WE, Rosenkranz SK, Schorr EN, Spartano NL, 6. Lobelo F, null null. Physical Activity as a Critical Component of First-Line Treatment for Elevated 400 401 Blood Pressure or Cholesterol: Who, What, and How?: A Scientific Statement From the American Heart Association. Hypertension. 2021;78:e26-e37. 402 403 7. Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of Different Dietary Interventions on Blood Pressure. Hypertension. 2016;67:733-739. 404 405 8. Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, Ma J, Ndumele CE, Schauer PR, Shimbo D, et al. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific 406 Statement From the American Heart Association. Hypertension. 2021;78:e38-e50. 407 Aladin AI, Chevli PA, Ahmad MI, Rasool SH, Herrington DM. Alcohol Consumption and Systemic 408 9. 409 Hypertension (from the Third National Health and Nutrition Examination Survey). The American 410 Journal of Cardiology. 2021;160:60-66. Jones DW, Whelton PK, Allen N, Clark D, Gidding SS, Muntner P, Nesbitt S, Mitchell NS, 411 10. 412 Townsend R, Falkner B, et al. Management of Stage 1 Hypertension in Adults With a Low 10-Year 413 Risk for Cardiovascular Disease: Filling a Guidance Gap: A Scientific Statement From the American Heart Association. Hypertension. 2021;77:e58-e67. 414

It is made available under a CC-BY 4.0 International license .

- 415 11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on
 416 Cost-Effectiveness in Health and Medicine. *JAMA*. 1996;276:1253–1258.
- 417 12. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, Williams L,
 418 Bibbins-Domingo K, Coxson PG, Goldman L. Cost-Effectiveness of Hypertension Therapy
 419 According to 2014 Guidelines. *N Engl J Med.* 2015;372:447–455.
- Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D,
 Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous
 Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. *JAMA*. 2016;316:743–
 753.
- Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevat J,
 Weinstein MC. The recent decline in mortality from coronary heart disease, 1980-1990. The effect
 of secular trends in risk factors and treatment. *JAMA*. 1997;277:535–542.
- Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent Overweight and
 Future Adult Coronary Heart Disease. *New England Journal of Medicine*. 2007;357:2371–2379.
- Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, JacobsJr.
 DR, Kronmal R, Liu K, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and Design. *American Journal of Epidemiology*. 2002;156:871–881.
- Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA,
 Mittelmark MB, Newman A, et al. The cardiovascular health study: Design and rationale. *Annals of Epidemiology*. 1991;1:263–276.
- Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR, Liu K, Savage PJ.
 Cardia: study design, recruitment, and some characteristics of the examined subjects. *Journal of Clinical Epidemiology*. 1988;41:1105–1116.
- KANNEL WB, FEINLEIB M, McNAMARA PM, GARRISON RJ, CASTELLI WP. AN
 INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES: THE FRAMINGHAM
 OFFSPRING STUDY. American Journal of Epidemiology. 1979;110:281–290.
- 441 20. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, Stamm E, Newman
 442 AB. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. *Journal of*443 *Applied Physiology*. 2001;90:2157–2165.
- 444 21. National Health and Nutrition Examination Survey, 2015–2018 : sample design and estimation
 445 procedures [Internet]. [cited 2023 Apr 11]; Available from: https://stacks.cdc.gov/view/cdc/88305
- 446 22. HCUP-US NIS Overview [Internet]. [cited 2022 Oct 11];Available from: https://www.hcup-us.ahrq.gov/nisoverview.jsp
- 448 23. Medical Expenditure Panel Survey Home [Internet]. [cited 2023 Apr 11];Available from: https://meps.ahrq.gov/mepsweb/
- 450 24. Gacutan K. HEALTHCARE COST AND UTILIZATION PROJECT HCUP. 2020;53.

- 451 25. Underlying Cause of Death 1999-2020 [Internet]. [cited 2023 Jan 30]; Available from:
 452 https://wonder.cdc.gov/wonder/help/ucd.html#
- 453 26. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L,
 454 Chaiyakunapruk N, Greenberg D, Loder E, et al. Consolidated Health Economic Evaluation
 455 Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health
 456 economic evaluations. *BMC Medicine*. 2022;20:23.
- 457 27. McEvoy JW, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM,
 458 Coresh J, Selvin E. Association of Isolated Diastolic Hypertension as Defined by the 2017
 459 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. *JAMA*.
 460 2020;323:329–338.
- 461 28. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P,
 462 Lackland DT, Levy D, O'Donnell CJ, et al. 2013 ACC/AHA Guideline on the Assessment of
 463 Cardiovascular Risk. *Circulation*. 2014;129:S49–S73.
- 464 29. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. :779.
- 465 30. Dietary Guidelines for Americans, 2020-2025.
- 466 31. Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD. Hypertension Control in the United
 467 States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age468 and Race-Ethnicity Groups. *Hypertension*. 2021;78:578–587.
- 469 32. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM,
 470 Cutler JA, Windhauser MM, et al. A Clinical Trial of the Effects of Dietary Patterns on Blood
 471 Pressure. *N Engl J Med.* 1997;336:1117–1124.
- 33. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of Weight Reduction on Blood
 Pressure: A Meta-Analysis of Randomized Controlled Trials. *Hypertension*. 2003;42:878–884.
- 474 34. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure.
 475 *Cochrane Database Syst Rev.* 2013;CD004937.
- 476 35. Whelton SP, Chin A, Xin X, He J. Effect of Aerobic Exercise on Blood Pressure. *Ann Intern Med.*477 2002;136:493–503.
- 36. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. *The Lancet Public Health*. 2017;2:e108–e120.
- 37. Zhang Y, Vittinghoff E, Pletcher MJ, Allen NB, Zeki Al Hazzouri A, Yaffe K, Balte PP, Alonso A,
 Newman AB, Ives DG, et al. Associations of Blood Pressure and Cholesterol Levels During
 Young Adulthood With Later Cardiovascular Events. *J Am Coll Cardiol*. 2019;74:330–341.
- 484 38. Lantz PM. The Medicalization of Population Health: Who Will Stay Upstream? *The Milbank* 485 *Quarterly*. 2019;97:36.
- 486 39. Kris-Etherton PM, Petersen KS, Després J-P, Anderson CAM, Deedwania P, Furie KL, Lear S,
 487 Lichtenstein AH, Lobelo F, Morris PB, et al. Strategies for Promotion of a Healthy Lifestyle in

It is made available under a CC-BY 4.0 International license .

488 Clinical Settings: Pillars of Ideal Cardiovascular Health: A Science Advisory From the American Heart Association. Circulation. 2021;CIR.000000000001018. 489 490 40. Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 491 2020;324:1190-1200. 492 Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, Zhang J, Tian M, Huang L, Li Z, et al. Effect of 493 41. 494 Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385:1067-1077. 495 42. Yin X, Paige E, Tian M, Li Q, Huang L, Yu J, Rodgers A, Elliott P, Wu Y, Neal B. The Proportion 496 of Dietary Salt Replaced With Potassium-Enriched Salt in the SSaSS: Implications for Scale-Up. 497 Hypertension. 2023;HYPERTENSIONAHA.122.20115. 498 Nutrition C for FS and A. Guidance for Industry: Voluntary Sodium Reduction Goals [Internet]. 43. U.S. Food and Drug Administration. 2022 [cited 2023 Mar 17]; Available from: 499 500 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-501 voluntary-sodium-reduction-goals 502 Millett C, Laverty AA, Stylianou N, Bibbins-Domingo K, Pape UJ. Impacts of a National Strategy 44. 503 to Reduce Population Salt Intake in England: Serial Cross Sectional Study. PLOS ONE. 504 2012;7:e29836. 505 Bell CN, Kerr J, Young JL. Associations between Obesity, Obesogenic Environments, and 45. 506 Structural Racism Vary by County-Level Racial Composition. Int J Environ Res Public Health [Internet]. 2019 [cited 2019 Apr 17];16. Available from: 507 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427384/ 508 509 46. Koohsari MJ, McCormack GR, Nakaya T, Oka K. Neighbourhood built environment and 510 cardiovascular disease: knowledge and future directions. Nat Rev Cardiol. 2020;17:261-263. 511 Step it Up! The Surgeon General's Call to Action to Promote Walking and Walkable Communities. 47. 512 48. CDC. Overcoming Barriers to Physical Activity [Internet]. Centers for Disease Control and 513 Prevention. 2022 [cited 2023 Jan 30]; Available from: 514 https://www.cdc.gov/physicalactivity/basics/adding-pa/barriers.html 515 49. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. The Lancet. 2017;389:1453-1463. 516 O'Neil CE, Nicklas TA, Keast DR, Fulgoni VL. Ethnic disparities among food sources of energy 517 50. 518 and nutrients of public health concern and nutrients to limit in adults in the United States: NHANES 2003-2006. Food Nutr Res. 2014;58:15784. 519 520 521

It is made available under a CC-BY 4.0 International license .

523

J					
	Stage 1 systolic hypertension [†]				
Characteristics	Men (N=152)	Women (N=186)			
Age, years	47.0 (1.4)	50.4 (0.7)			
Systolic BP, mmHg	133.6 (0.3)	133.7 (0.3)			
Diastolic BP, mmHg	78.5 (0.9)	76.5 (0.9)			
Predicted 10-year CVD risk, %	4.7 (0.4)	2.3 (0.2)			
Non-pharmacological risk factors					
Overweight or obese, %	80.2	78.6			
Physically inactive, %	29.9	44.8			
High sodium intake, %	91.9	71.1			
Low fruit and vegetable intake, %	57.4	62.6			
High alcohol consumption, %	27.9	16.6			
Healthcare access					
Health insurance type, %					
Public insurance	6.2	11.3			
Private insurance	77.8	78.5			
No insurance	16.0	10.2			
Regular source of healthcare, %	71.3	82.9			
Healthcare visits in past year, %					
None	32.5	11.6			
One	19.4	28.3			
Two or more	48.1	60.1			

Table 1. Characteristics of U.S. population aged 35-64 years with 2017 ACC/AHAstage 1 systolic hypertension recommended nonpharmacologic therapy,* NHANESyears 2015-2018

Values are mean (standard error) or %. Estimates calculated using survey sample weighting procedures on data collected from National Health and Nutrition Examination Survey years 2015-2018. N reflects the number of NHANES participants for each subgroup.

ACC = American College of Cardiology; AHA = American Heart Association; BP = blood pressure; NHANES – National Health and Nutrition Survey

^{*}The 2017 ACC/AHA guideline defines stage 1 hypertension as having a systolic blood pressure of 130 to 139 mmHg or a diastolic blood pressure of 80 to 89 mmHg and recommends non-pharmacological BP management for those without diabetes, chronic kidney disease, or cardiovascular disease and less than 10% risk of a CVD event within 10 years calculated using the Pooled Cohort Risk Equations

[†] Stage 1 systolic hypertension defined as systolic BP ranging from 130 - 139 mmHg and diastolic BP < 90 mmHg

	Population reached (millions)	Number of events prevented and healthcare costs saved (95% Confidence Intervals)				
Simulated target group		Incident CVD**	Total myocardial infarctions***	Total strokes***	CVD mortality	Healthcare cost savings ¥ (millions 2019 USD)
Men	•					
Full target population	4.2	15,300 (13,100 – 18,200)	4,100 (3,300 – 5,000)	5,400 (4,500 - 6,600)	1,600 (1,300 – 1,800)	\$955 (\$832 – \$1,131)
with regular healthcare	2.1	7,700 (6,600 – 9,200)	2,100 (1,700 – 2,500)	2,800 (2,300 – 3,400)	800 (700 – 900)	\$486 (\$423 – \$575)
Women						
Full target population	4.6	10,800 (9,500 – 12,500)	2,600 (2,200 – 3,100)	5,000 (4,200 – 6,000)	1,300 (1,100 – 1,500)	\$712 (\$624 – \$830)
Subgroup with regular healthcare access	3.4	8,100 (7,200 – 9,400)	2,000 (1,700 – 2,300)	3,800 (3,200 – 4,500)	1,000 (900 – 1,100)	\$534 (\$468 – \$621)

Table 2. Projected impact of controlling SBP to under 130 mmHg in adults with stage 1 hypertension recommended onlynonpharmacologic therapy by the 2017 ACC/AHA BP guideline*, 2018-2027

Values are numbers of events and healthcare costs when controlling systolic BP to 129 mmHg compared to status quo systolic BP over 10 years.

ACC = American College of Cardiology; AHA = American Heart Association; CVD = cardiovascular disease

*Simulations include those with systolic BP ranging from 130 to 139 mmHg, diastolic BP under 90 mmHg and no indicator of high CVD risk (diabetes, chronic kidney disease, cardiovascular disease, or >=10% predicted risk of a CVD event within 10 years)

**Includes myocardial infarction, cardiac arrest, angina, ischemic stroke and hemorrhagic stroke occurring in the CVD free population

***Includes myocardial infarction or ischemic stroke and hemorrhagic stroke occurring in the population with and without history of CVD

¥ Total healthcare costs are undiscounted and include costs from hospitalizations for MI, stroke, cardiac arrest, and revascularization procedures; chronic CVD outpatient care; and background costs for non-cardiovascular care

guideline ^a , 2018-2027						
	Number of events prevented and healthcare costs saved (95% Confidence Intervals)					
Simulated intervention*	Population reached (millions)	Incident CVD **	Total myocardial infarctions***	Total stroke events***	CVD mortality	Healthcare costs savings¥ (millions 2019 USD)
DASH diet adherence	8.8	28,000 (18,100 - 38,400)	7,200 (4,600 – 10,000)	11,300 (7,200 – 15,500)	3,100 (2,000 – 4,200)	\$1,794 (\$1,191 – \$2,405)
Sustained weight loss	6.9	19,500 (15,200 – 24,200)	5,000 (3,800 - 6,300)	7,900 (5,900 – 10,000)	2,100 (1,600 – 2,600)	\$1,247 (\$987 – \$1,523)
Reduced sodium intake	7.1	17,900 (13,300 – 22,700)	4,600 (3,400 - 6,000)	7,100 (5,200 – 9,200)	1,900 (1,400 – 2,500)	\$1,141 (\$865 – \$1,434)
Increased fruit and vegetable intake	8.3	13,800 (3,400 – 23,000)	3,500 (1,000 – 5,900)	5,600 (1,500 – 9,300)	1,500 (400 – 2,500)	\$884 (\$287 – \$1,447)
Sufficient physical activity	3.3	7,200 (5,100 – 9,500)	1,800 (1,300 – 2,400)	3,000 (2,000 – 4,000)	800 (600 – 1,100)	\$461 (\$330 – \$596)
Moderated alcohol intake	1.9	3,700 (2,800 – 4,900)	1,000 (700 – 1,300)	1,500 (1,100 – 1,900)	400 (300 – 500)	\$239 (\$180 – \$308)

Table 3 Projected impact of evidence-based nonpharmacological therapy in adults with stage 1 hypertension by 2017 ACC/AHA BP

^a 2017 ACC/AHA BP guideline recommend only nonpharmacological therapy for those with SBP ranging from 130 to 139 mmHg, diastolic BP under 90 mmHg and no indicator of high CVD risk (diabetes, chronic kidney disease, cardiovascular disease, or >=10% predicted risk of a CVD event within 10 years)

*Each estimate reflects contrasts in outcomes between SBP reductions due to the simulated intervention and no change in systolic BP among the target population. Interventions were applied only to adults in the target population whose health behaviors fall below recommended thresholds. The DASH diet intervention applied to the full target population; the sustained weight loss intervention applied adults who are overweight or obese; the dietary sodium intervention applied to adults currently consuming excessive sodium; the physical activity intervention applied to adults who engage in insufficient weekly metabolic equivalents of task; and the alcohol reduction intervention applied to adults currently consuming higher than recommended amounts of alcohol daily.

**Incident CVD includes myocardial infarction, cardiac arrest, angina, ischemic and hemorrhagic stroke occurring in the CVD free population

***Includes myocardial infarction or ischemic stroke and hemorrhagic stroke occurring in the population with and without history of

CVD

¥ Total healthcare costs are undiscounted and include costs from hospitalizations for MI, stroke, cardiac arrest, and revascularization procedures; chronic CVD outpatient care; and background costs for non-cardiovascular care

Figure 1. Projected 10-year reduction in incident cardiovascular disease events for evidence-based non-pharmacological approaches to reducing blood pressure among adults with and without self-reported regular healthcare utilization. Simulations

targeted adults with stage 1 systolic hypertension (SBP 130 – 139 mmHg and DBP <90) who qualify for nonpharmacological therapy in the 2017 ACC/AHA guidelines. We simulated effect of the DASH diet in those not currently eating a DASH dietary pattern (assumed to be everyone in the target population), sustained weight loss in adults who are overweight or obese (80% of men and 79% of women), reduced sodium intake in those currently consuming ≥ 2300 mg/day (92% of men and 71% of women), increasing fruit and vegetable intake in those not currently eating at least 2.5 cups of vegetables and 2 cups of fruit per day (94% of men and 96% of women), sufficient physical activity for inactive adults (<600 weekly metabolic physical equivalents of task; 30% of men and 45% of women), and reductions in alcohol intake for men and women drinking more than 2 or 1 drink per day, respectively (28% of men and 17% of women). 49% of men and 27% of women reported not having regular healthcare: i.e., being uninsured, not having a routine place to receive healthcare, or not visiting a healthcare professional in a non-emergency room context in the previous 12 months.

